{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:58:34Z","timestamp":1785419914620,"version":"3.56.0"},"reference-count":15,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Almirall S.p.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Topical medications are commonly used to manage mild\u2011to\u2011moderate psoriasis as adjunctive treatments in patients receiving phototherapy, systemic agents or biologic therapies. Amongst available topical options, the fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) has demonstrated efficacy and tolerability in clinical trials, with most adverse events being mild and transient local reactions. CAL\/ BDP has recently been formulated as a cream using polyaphron dispersion (PAD) technology to improve its rheological behaviour and sensory characteristics. We describe the use of CAL\/BDP PAD\u2011based cream specifically in patients with mild\u2011to\u2011moderate psoriasis across four Italian centres. The first case involves a man with mild-to-moderate scalp psoriasis, in whom CAL\/BDP PAD\u2011based cream was effective in this high\u2011impact disease location. The second case focuses on a patient with pretibial psoriasis, a difficult-to-treat site. The third case is of a woman with palmoplantar psoriasis who reported clinical improvement in the lesions and increased treatment compliance compared with her previous therapies. The last case describes the concomitant use of CAL\/BDP PAD-based cream with a biologic drug, resulting in optimized lesion clearance. CAL\/BDP PAD\u2011based cream appears promising for managing psoriasis in specific contexts such as lesions in difficult\u2011to\u2011treat areas or residual disease during biologic therapy. Further real\u2011world data and clinical observations will be important to clarify how this formulation can be integrated into individualized management strategies for mild-to-moderate psoriasis.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-therapeutic-outcomes-of-cal-bdp-pad-based-cream-in-patients-with-mild-to-moderate-psoriasis-insights-from-four-case-reports<\/jats:p>","DOI":"10.7573\/dic.2026-5-5","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:23:04Z","timestamp":1784020984000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic outcomes of CAL\/BDP PAD\u2011based cream in patients with mild-to-moderate psoriasis: insights from four case reports"],"prefix":"10.7573","author":[{"given":"Annunziata","family":"Dattola","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sechi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/016zn0y21","id-type":"ROR","asserted-by":"publisher"}],"name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05d538656","id-type":"ROR","asserted-by":"publisher"}],"name":"IRCCS Humanitas Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00pap0267","id-type":"ROR","asserted-by":"publisher"}],"name":"Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u2013470. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Praestegaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application. Dermatol Ther. 2022;12(10):2217\u20132231. https:\/\/doi.org\/10.1007\/s13555-022-00794-y","DOI":"10.1007\/s13555-022-00794-y"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Torres T, Galvan J, Crutchley N, et al. Calcipotriol and betamethasone dipropionate cream based on PAD technology for the treatment of plaque psoriasis: a narrative review. Dermatol Ther. 2023;13(10):2153\u20132169. https:\/\/ doi.org\/10.1007\/s13555-023-01003-0","DOI":"10.1007\/s13555-023-01003-0"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Pinter A, Green LJ, Selmer J, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(2):228\u2013236. https:\/\/doi.org\/10.1111\/jdv.17734","DOI":"10.1111\/jdv.17734"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Murdoch D, Clissold SP. Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs. 1992;43(3):415\u2013429. https:\/\/doi.org\/10.2165\/00003495-199243030-00007","DOI":"10.2165\/00003495-199243030-00007"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Pinter A, Reich A, Arenberger P, et al. Randomized phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2023;37(11):2327\u20132335. https:\/\/doi.org\/10.1111\/jdv.19330","DOI":"10.1111\/jdv.19330"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Pinter A, Gold LS, Reich A, et al. A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):14\u201319. https:\/\/doi.org\/10.1111\/jdv.18755","DOI":"10.1111\/jdv.18755"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Lopez Estebaranz JL, Kurzen H, Galvan J. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey. J Dermatolog Treat. 2024;35(1):2357618. https:\/\/doi.org\/10.1080\/ 09546634.2024.2357618","DOI":"10.1080\/09546634.2024.2357618"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Kin KC, Hill D, Feldman SR. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Expert Rev Clin Pharmacol. 2016;9(6):789\u2013797. https:\/\/doi.org\/10.1080\/17512433.2016.1179574","DOI":"10.1080\/17512433.2016.1179574"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Garcia N, Guiro P, Galvan J, et al. Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp. Drugs Context. 2023;12:2023-2-8. https:\/\/doi.org\/10.7573\/dic.2023-2-8","DOI":"10.7573\/dic.2023-2-8"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, doubleblind, controlled trial. J Am Acad Dermatol. 2008;59(3):455\u2013463. https:\/\/doi.org\/10.1016\/j.jaad.2008.04.027","DOI":"10.1016\/j.jaad.2008.04.027"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009;160(1):170\u2013176. https:\/\/doi.org\/10.1111\/ j.1365-2133.2008.08927.x","DOI":"10.1111\/j.1365-2133.2008.08927.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Bewley A, van de Kerkhof P. Engaging psoriasis patients in adherence and outcomes to topical treatments: a summary from the symposium \u2018Tailoring Topical Psoriasis Treatments to Patients\u2019 Needs and Expectations\u2019 of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):9\u201313. https:\/\/doi.org\/10.1111\/jdv.18751","DOI":"10.1111\/jdv.18751"},{"key":"ref13","unstructured":"14. Sojevic Timotijevic Z, Majcan P, Trajkovic G, et al. The impact of changes in Psoriasis Area and Severity Index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat. 2017;25(3):215\u2013222."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Puig L, Carrascosa JM, Belinchon I, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104(6):488\u2013496. https:\/\/doi.org\/10.1016\/j.ad.2012.12.005","DOI":"10.1016\/j.adengl.2012.12.003"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/07\/dic.2026-5-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:23:07Z","timestamp":1784020987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/therapeutic-outcomes-of-cal-bdp-pad-based-cream-in-patients-with-mild-to-moderate-psoriasis-insights-from-four-case-reports"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-5-5","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"9"}}